Form 4: BillionToOne Executive Executes Planned Stock Sale

John Roderick ten Bosch, Senior VP of Laboratory Operations at BillionToOne, sold 2,832 shares of Class A Common Stock via a 10b5-1 trading plan.

Summary

• John Roderick ten Bosch, Senior Vice President of Laboratory Operations at BillionToOne, Inc., sold a total of 2,832 shares of Class A Common Stock.
• The shares were sold in two equal tranches of 1,416 shares each at a price of $101.47 per share.
• The transactions were executed on June 15, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
• Following these transactions, the reporting person retains beneficial ownership of 34,968 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a standard executive financial management action rather than a reaction to company performance.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• Continued selling by insiders may be perceived negatively by retail investors, potentially impacting short-term stock price volatility.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common practice for executives in the biotechnology and diagnostics sectors to manage personal liquidity and is generally not indicative of a change in company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to divest shares while maintaining regulatory compliance.
• The scale of the sale relative to the executive's total holdings is consistent with typical periodic diversification strategies seen in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed via a pre-arranged plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

BillionToOne, BLLN, Insider Trading, Form 4, Equity Sale, Rule 10b5-1